• Lung
Name No. Patient Profile Purpose
AbbVie M14-239 18-49

locally advanced or metastatic non-small cell lung cancer previously treated with systemic cytotoxic therapy (or ineligible), and an immune checkpoint inhibitor (as monotherapy or in combination with systemic cytotoxic chemotherapy, or ineligible)

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2).


  • Lung
Name No. Patient Profile Purpose
INTENSE 15-47

For patients with non-small cell lung cancer (NSCLC) who are unsuitable for surgery or stereotactic ablative body radiation therapy (SABR)

The primary objective of this study is to assess the safe delivery of an achievable level of dose escalation in a dose‐escalated and
intensified radiation therapy regime delivered via VMAT/IMRT and focussed on the GTV, by the
proportion of grade ≥3 toxicities per NCI‐CTCAE V4 determined to be related to radiation
therapy.


  • Lung
Name No. Patient Profile Purpose
MK3475-495 17-34

Advanced non-small cell lung cancer (NSCLC) who are at least 18 years of age.

This trial will investigate the utility of biomarker-based triage for patients with advanced non-small cell lung cancer (NSCLC) without prior systemic therapy.


  • Lung
Name No. Patient Profile Purpose
ETOP 12-17 ALERT 16-59

Patients with advanced stage RET-rearranged NSCLC, treated with at least one platinum based systemic chemotherapy regimen.

The primary objective is to assess the efficacy of alectinib in terms of best overall response (OR) assessed by RECIST 1.1., from the start of trial treatment across all time points until the end of trial treatment


  • Lung
Name No. Patient Profile Purpose
MK3475-671 17-37

Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer

To assess the efficacy and safety of Pembrolizumab (MK-3475) with platinum doublet chemotherapy as neoadjuvant/adjuvant therapy for participants With resectable stage IIB or IIIA non-small cell lung cancer.